Clinical Trial

Investigating the Impact of Sex Hormones in Multiple Sclerosis

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Emerging evidence indicates that females with MS experience worsened symptoms during the luteal phase (post ovulation) of the menstrual cycle when progesterone levels rise and estradiol fluctuate. The rapid hormonal swings may disrupt hypothalamic regulation, leading to an increase in body temperature - a well-established trigger for MS symptom exacerbation. These hormonal changes could also affect neuromuscular function, as estradiol and progesterone receptors are present in the nervous system and skeletal muscles. Three critical aspects of motor rehabilitation are corticospinal excitability, motor learning, and fatigability. Previous research indicates that corticospinal excitability and the capacity to learn fine motor tasks fluctuate across menstrual cycles, indicating hormonal influences on neuroplasticity. However, it remains unclear how these hormonal fluctuations specifically affect corticospinal excitability, motor learning, and motor fatigability in females with MS. Understanding these relationships could significantly improve rehabilitation approaches. For example, pre-menopause females with MS may experience a more optimal state for neuroplasticity during the follicular phase of their cycles, therefore providing a potential window for greater rehabilitation efficacy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-22.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-03-18
Trial Details
NCT Number NCT07081594
Lead Sponsor Milap Sandhu
Conditions Multiple Sclerosis
Enrollment 14 participants
Start Date 2025-08-28
Primary Completion 2027-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-03-20